Lab
Natural State Laboratories, LLC
Natural State Laboratories, LLC was paid $513K by Medicaid between Mar 2019 and Feb 2024, across 118 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 35% of everything it billed.
33Billing provider infoNATURAL STATE LABORATORIES, LLC
LITTLE ROCK, AR 72211
LITTLE ROCK, AR 72211
33aNPI1730658279assigned 11/14/2018
33bProvider typeClinical Medical Laboratory
28Total paid$513K
24GClaims83,609
24DCodes billed118
24AFirst – last monthMar 2019 – Feb 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Arkansas
Rank by total paid#9 of 24
Median peer was paid$53K
This provider vs. median9.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 2,564 | $47K | |
| 2020 | 3,895 | $46K | |
| 2021 | 6,535 | $111K | |
| 2022 | 11,278 | $150K | |
| 2023 | 51,622 | $141K | |
| 2024incomplete | 7,715 | $19K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 35% | 6,746 | 4,147 | $180K |
| 80361 | 5.2% | 2,113 | 1,657 | $27K | |
| 80346 | 4.1% | 1,982 | 1,516 | $21K | |
| 80348 | 3.9% | 1,911 | 1,471 | $20K | |
| 80365 | 3.6% | 1,908 | 1,466 | $18K | |
| 80358 | 3.4% | 1,669 | 1,271 | $18K | |
| 80324 | 3.4% | 1,916 | 1,480 | $17K | |
| 80353 | 3.2% | 1,831 | 1,443 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.1% | 1,650 | 1,495 | $16K |
| 80345 | 3.0% | 952 | 743 | $16K | |
| 80050 | General health panel | 2.7% | 282 | 279 | $14K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 188 | 172 | $12K |
106 more codes
| 80061 | Lipid panel | 2.0% | 2,679 | $10K |
| 80053 | Comprehensive metabolic panel | 1.7% | 5,253 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 7,009 | $9K |
| 80356 | 1.4% | 931 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 2,846 | $7K |
| 80306 | 1.1% | 1,398 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 83 | $4K |
| 80362 | <1% | 1,044 | $4K | |
| 80354 | <1% | 1,037 | $4K | |
| 80372 | <1% | 863 | $4K | |
| 80375 | <1% | 920 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 81 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,521 | $4K |
| 80355 | <1% | 847 | $4K | |
| 80366 | <1% | 801 | $3K | |
| 80368 | <1% | 792 | $3K | |
| 80371 | <1% | 713 | $3K | |
| 80164 | <1% | 1,034 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,359 | $3K |
| 82607 | <1% | 731 | $3K | |
| 83880 | <1% | 451 | $3K | |
| 80369 | <1% | 965 | $2K | |
| 80177 | <1% | 619 | $2K | |
| 80373 | <1% | 386 | $2K | |
| 80359 | <1% | 812 | $2K | |
| 80349 | <1% | 187 | $2K | |
| 84480 | <1% | 468 | $1K | |
| 87481 | <1% | 83 | $1K | |
| 83735 | <1% | 1,005 | $1K | |
| 84439 | <1% | 642 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 83 | $1K |
| 80334 | <1% | 89 | $1K | |
| 80347 | <1% | 62 | $961.11 | |
| 87500 | <1% | 83 | $936.23 | |
| 87541 | <1% | 83 | $926.45 | |
| 87581 | <1% | 83 | $926.45 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 83 | $923.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 83 | $922.90 |
| 87486 | <1% | 81 | $893.31 | |
| 87653 | <1% | 83 | $830.79 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 99 | $821.28 |
| 87641 | <1% | 81 | $800.58 | |
| 82746 | <1% | 150 | $693.00 | |
| 81003 | <1% | 1,572 | $667.77 | |
| 87181 | <1% | 83 | $649.63 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 463 | $564.97 |
| 80185 | <1% | 170 | $530.04 | |
| 82728 | <1% | 109 | $486.50 | |
| 80321 | <1% | 122 | $462.35 | |
| 80364 | <1% | 73 | $460.82 | |
| 83540 | <1% | 305 | $443.50 | |
| 82140 | <1% | 132 | $416.35 | |
| 85610 | <1% | 378 | $398.31 | |
| 80332 | <1% | 114 | $316.92 | |
| 80338 | <1% | 114 | $303.84 | |
| 80323 | <1% | 76 | $297.06 | |
| 80325 | <1% | 20 | $266.49 | |
| 80335 | <1% | 67 | $233.84 | |
| 84134 | <1% | 66 | $229.77 | |
| 80357 | <1% | 76 | $229.60 | |
| 80360 | <1% | 76 | $229.60 | |
| 80076 | <1% | 78 | $209.45 | |
| 84550 | <1% | 117 | $207.04 | |
| 83001 | <1% | 19 | $195.14 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,312 | $171.64 |
| 80178 | <1% | 53 | $156.06 | |
| 83789 | <1% | 64 | $128.95 | |
| 80329 | <1% | 76 | $127.49 | |
| 84100 | <1% | 127 | $115.26 | |
| 82550 | <1% | 132 | $80.57 | |
| 82150 | <1% | 21 | $68.06 | |
| 80051 | <1% | 124 | $66.64 | |
| 80320 | <1% | 56 | $64.88 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,898 | $60.27 |
| 82947 | <1% | 106 | $59.95 | |
| 82310 | <1% | 124 | $49.11 | |
| 82040 | <1% | 104 | $45.46 | |
| 84520 | <1% | 126 | $44.83 | |
| 82247 | <1% | 94 | $43.32 | |
| 84146 | <1% | 16 | $27.67 | |
| 84075 | <1% | 88 | $25.36 | |
| 84450 | <1% | 97 | $25.08 | |
| 84460 | <1% | 89 | $23.92 | |
| 80350 | <1% | 13 | $22.96 | |
| 86140 | <1% | 16 | $22.17 | |
| 80337 | <1% | 47 | $20.49 | |
| 84155 | <1% | 88 | $18.00 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 3,637 | $16.50 |
| 84153 | <1% | 22 | $10.00 | |
| 81225 | 0% | 25 | $0.00 | |
| 81231 | 0% | 20 | $0.00 | |
| 81226 | 0% | 28 | $0.00 | |
| 80367 | 0% | 47 | $0.00 | |
| 86409 | 0% | 95 | $0.00 | |
| 81227 | 0% | 20 | $0.00 | |
| 81240 | 0% | 20 | $0.00 | |
| 81230 | 0% | 27 | $0.00 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 453 | $0.00 |
| 81401 | 0% | 21 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 31 | $0.00 |
| 81241 | 0% | 20 | $0.00 | |
| 81328 | 0% | 22 | $0.00 | |
| 86413 | 0% | 95 | $0.00 | |
| 81291 | 0% | 27 | $0.00 | |
| 81335 | 0% | 20 | $0.00 | |
| 81355 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHONEYCUTT, CASEY (EVP)
| Provider | Location | Paid |
|---|---|---|
| Natural State Genomics LLC | Little Rock, AR | $4.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.